Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial

Urs Zimmermann, Christoph Rudin, Angelo Duò, Leonhard Held, Hans Ulrich Bucher, Swiss neonatal abstinence syndrome study group, Urs Zimmermann, Christoph Rudin, Angelo Duò, Leonhard Held, Hans Ulrich Bucher, Swiss neonatal abstinence syndrome study group

Abstract

Three suitable compounds (morphine, chlorpromazine, and phenobarbital) to treat neonatal abstinence syndrome were compared in a prospective multicenter, double-blind trial. Neonates exposed to opioids in utero were randomly allocated to one of three treatment groups. When a predefined threshold of a modified Finnegan score was reached, treatment started and increased stepwise until symptoms were controlled. If symptoms could not be controlled with the predefined maximal dose of a single drug, a second drug was added. Among 143 infants recruited, 120 needed pharmacological treatment. Median length of treatment for morphine was 22 days (95% CI 18 to 33), for chlorpromazine 25 days (95% CI 21 to 34), and for phenobarbital 32 days (95% CI 27 to 38) (p = ns). In the morphine group, only 3% of infants (1/33) needed a second drug; in the chlorpromazine group, this proportion was 56% (24/43), and in the phenobarbital group 30% (13/44).Conclusion: None of the drugs tested for treating neonatal abstinence syndrome resulted in a significantly shorter treatment length than the others. As morphine alone was able to control symptoms in almost all infants, it may be preferred to the two other drugs but should still be tested against more potent opioids such as buprenorphine.Trial registration: At ClinicalTrials.gov NCT02810782 (registered retrospectively).What is Known:• Neonates exposed to opiates in utero and presenting with withdrawal symptoms should first be treated by non-pharmacological supportive measures.• In those who fail, drugs have to be given, but there is controversy which drug is best.What is New:• Among three candidates, morphine, chlorpromazine and phenobarbital, none resulted in significantly shorter treatment time.• As morphine alone was able to control symptoms in almost all infants, it may be preferred to the two other drugs.

Keywords: Chlorpromazine; Morphine; Neonate; Opioids; Pharmacological treatment; Phenobarbital; Withdrawal.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Therapy algorithm. Medications are started, increased, decreased, or stopped depending on a modified Finnegan score. If symptoms were not controlled by the predefined maximal dose of the first allocated drug, a second drug was added following the same algorithm as the first drug
Fig. 2
Fig. 2
Flow diagram (reference CONSORT 2010)
Fig. 3
Fig. 3
Kaplan-Meier and log cumulative hazard curves for treatment length and for hospitalization length. p values of a log-rank test are added. The time-to-event curves in the Kaplan-Meier plots can be interpreted as the complementary empirical distribution functions

References

    1. Allegaert K, Sherwin C. Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. Eur J Pediatr. 2016;175:743–746. doi: 10.1007/s00431-015-2686-2.
    1. Allegaert K, van den Anker JN. Neonatal withdrawal syndrome: reaching epidemic proportions across the globe. Arch Dis Child Fetal Neonatal Ed. 2016;101:F2–F3. doi: 10.1136/archdischild-2015-309566.
    1. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92:208–217. doi: 10.1093/bja/aeh042.
    1. Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24:682–701. doi: 10.1016/S0197-2456(03)00072-2.
    1. Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction. 2017;112:1590–1599. doi: 10.1111/add.13842.
    1. Disher T, Gullickson C, Singh B, Cameron C, Boulos L, Beaubien L, Campbell-Yeo M. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatr. 2019;173:234–243. doi: 10.1001/jamapediatrics.2018.5044.
    1. Eze N, Smith LM, LaGasse LL, Derauf C, Newman E, Arria A, Huestis MA, Della Grotta SA, Dansereau LM, Neal C, Lester BM. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the infant development, environment, and lifestyle study. J Pediatr. 2016;170:34–38.e31. doi: 10.1016/j.jpeds.2015.11.070.
    1. Gomez-Pomar E, Finnegan LP. The epidemic of neonatal abstinence syndrome, historical references of its origins, assessment, and management. Front Pediatrics. 2018;6:33. doi: 10.3389/fped.2018.00033.
    1. Held-Egli K, Ruegger C, Das-Kundu S, Schmitt B, Bucher HU. Benign neonatal sleep myoclonus in newborn infants of opioid dependent mothers. Acta Paediatr. 2009;98:69–73. doi: 10.1111/j.1651-2227.2008.01010.x.
    1. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012;129:e540–e560. doi: 10.1542/peds.2011-3212.
    1. Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2004;89:F300–F304. doi: 10.1136/adc.2003.033555.
    1. Jones HE, Fielder A. Neonatal abstinence syndrome: historical perspective, current focus, future directions. Prev Med. 2015;80:12–17. doi: 10.1016/j.ypmed.2015.07.017.
    1. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134:e547–e561. doi: 10.1542/peds.2013-3524.
    1. Largo RH, Graf S, Kundu S, Hunziker U, Molinari L. Predicting developmental outcome at school age from infant tests of normal, at-risk and retarded infants. Dev Med Child Neurol. 1990;32:30–45. doi: 10.1111/j.1469-8749.1990.tb08464.x.
    1. Lava SAG, Elie V, Ha PTV, Jacqz-Aigrain E. Sequential analysis in neonatal research—systematic review. Eur J Pediatr. 2018;177:733–740. doi: 10.1007/s00431-018-3110-5.
    1. Mazurier EE, Cambonie G, Barbotte E, Grare A, Pinzani V, Picaud JC. Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome. Acta Paediatr. 2008;97:1358–1361. doi: 10.1111/j.1651-2227.2008.00918.x.
    1. Morrison CL, Siney C. A survey of the management of neonatal opiate withdrawal in England and Wales. Eur J Pediatr. 1996;155:323–326. doi: 10.1007/BF02002721.
    1. Nayeri F, Sheikh M, Kalani M, Niknafs P, Shariat M, Dalili H, Dehpour AR. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatr. 2015;15:57–57. doi: 10.1186/s12887-015-0377-9.
    1. O’Grady MJ, Hopewell J, White MJ. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed. 2009;94:F249–F252. doi: 10.1136/adc.2008.152769.
    1. Osborn DA, Jeffery HE, Cole MJ (2010) Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev:CD002053. 10.1002/14651858.CD002053.pub3
    1. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, Clark RH, Spitzer AR. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372:2118–2126. doi: 10.1056/NEJMsa1500439.
    1. Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr. 2014;165:440–446. doi: 10.1016/j.jpeds.2014.05.010.
    1. Zimmermann-Baer U, Notzli U, Rentsch K, Bucher HU. Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction. 2010;105:524–528. doi: 10.1111/j.1360-0443.2009.02802.x.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel